Indications

Vision SAP supplies a daily dose of antioxidants, nutraceuticals, carotenoids and vitamins for the prevention of macular degeneration (a degenerative /condition of the macula, the central retina) and cataracts (a clouding of the natural lens, the part of the eye responsible for focusing light and producing clear, sharp images). This formula's individual components have been scientifically demonstrated to aid in the blood circulation and for the support and trasport of vital nutrients into the macular region for protection from oxidative stress. These components have been widely used for teh treatment of eye disease yet, the scientific evidnece of the combined formula has not yet been proven.

Ingredients

Alpha Lipoic Acid 200mg
Ginkgo Biloba 24% - 6% 120mg
Multi anthocyanidins 20% 100mg
Lutein 10% 100mg
Bilberry 25% 100mg
Astaxanthin 2% 20mg
Zeaxanthin 20% 20mg
Zinc citrate 15mg
Niacin B3 5.1mg
Copper gluconate 3.6mg
Seleniomethionine 0.9mg
d'alpha tocopherol acetate 17 i.u.

Description

STANDARDIZED EXTRACTS
Vision SAP delivers this formula with specified levels fo one or more plant constituents. The idea of using standardized extracts is to establish a consistent potency and to control the full spectrum of bioactive chemical constituents naturally occurring in medicinal plants. Standarization ensures that consistent botanical materials are produced batch to batch using the appropriate preparation of quality starting materials. Standardization can help ensure that consistent botanical materials are produced.

PURITY AND STABILITY
Third party testing on finished product to ensure Vision SAP is guaranteed 99% pure and free of heavy metals, PCB's, pesticides, volatile organics and other impurities.

Quantity

60 capsules

Dose

1 or 2 capsules once or twice daily with meals or as directed by your physician

References

"Show references"

"Hide references"

1. Alves-Rodrigues A, Shao A. Toxicol Lett 2004;150:57-83. 2. Bartlett H, Eperjesi F. Ophthal Physiol Opt 2004;24:339-49. 3. Guerin M, Huntley ME, Olaizola M. Trends Biotechnol 2003;21:210-16. 4. Head K. Altern Med Rev 2001;6:141-66. 5. Muth ER, Laurent JM, Jasper P. Altern Med Rev 2000;5:164 -73. 6. Bartlett H, Eperjesi F. Ophthal Physiol Opt 2003;23:383-99. 7. Metelitsina TI et al. Br J Ophthalmol 2004;88:1568-72. 8. Karakucuk S et al. Acta Ophthalmol Scand 1995;73:329-32 9. Borenshtein D et al. Diabetes Metab Res Rev 2001;17:44-50.